RG
BLUE

Redmile Group’s bluebird bio BLUE Stock Holding History

Redmile Group’s Portfolio BLUE Stock Details BLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-19,462
Closed -$36.8M – 81
2018
Q3 		$36.8M Sell
19,462
-1,266
-6% -$2.62M 1.13% 31
2018
Q2 		$42.1M Buy
20,728
+108
+0.5% +$246K 1.43% 25
2018
Q1 		$45.6M Buy
20,620
+563
+3% +$1.43M 1.76% 22
2017
Q4 		$46.3M Buy
+20,057
New +$40.7M 2.01% 19
2015
Q1 		– Sell
-7,892
Closed -$9.38M – 56
2014
Q4 		$9.38M Buy
+7,892
New +$5.27M 1.02% 35

Other funds holding BLUE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Redmile Group's BLUE Position: Q4 2018 in Review

Redmile Group sold out of bluebird bio (BLUE) in Q4 2018, closing a stake of 19,462 shares — an estimated $36.8M sold.

Redmile Group first reported a position in BLUE in Q4 2014 and held it in 5 quarters. The position peaked at $46.3M in Q4 2017. 251 funds tracked by Wall St. Rank hold BLUE as of Q4 2018.

  • Redmile Group reported no remaining bluebird bio position as of Q4 2018 after selling out during the quarter.
  • Redmile Group sold 19,462 bluebird bio shares in Q4 2018, an estimated $36.8M.
  • Redmile Group first reported a position in bluebird bio in Q4 2014 and held it in 5 quarters.
  • Redmile Group's bluebird bio position peaked at $46.3M in Q4 2017.
  • 251 funds tracked by Wall St. Rank held bluebird bio as of Q4 2018.

Based on Redmile Group's 13F filing for Q4 2018, filed 14 Feb 2019.